Operationalizing the scope of the Medicare drug negotiations

The Inflation Reduction Act of 2022 allowed Medicare to directly negotiate the prices of certain high-expenditure, single-source drugs without generic or biosimilar competition. The first set of negotiated prices will take effect in 2026. The Centers for Medicare and Medicaid Services has announced the second set of drugs selected for the negotiation program. Rachel Sachs and Richard G. Frank for Brookings analyzed the expansion of the Medicare drug price negotiation program. Read their analysis here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.